Literature DB >> 26596947

In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.

Mahipal G Sinnollareddy1, Michael S Roberts1, Jeffrey Lipman2, Melissa Lassig-Smith3, Therese Starr3, Thomas Robertson1, Sandra L Peake4, Jason A Roberts5.   

Abstract

The objective of the study was to describe the subcutaneous interstitial fluid (ISF) pharmacokinetics of fluconazole in critically ill patients with sepsis. This prospective observational study was conducted at two tertiary intensive care units in Australia. Serial fluconazole concentrations were measured over 24 h in plasma and subcutaneous ISF using microdialysis. The concentrations in plasma and microdialysate were measured using a validated high-performance liquid chromatography system with electrospray mass spectrometer detector method. Noncompartmental pharmacokinetic analysis was performed. Twelve critically ill patients with sepsis were enrolled. The mean in vivo fluconazole recovery rates ± standard deviation (SD) for microdialysis were 51.4% ± 16.1% with a mean (±SD) fluconazole ISF penetration ratio of 0.52 ± 0.30 (coefficient of variation, 58%). The median free plasma area under the concentration-time curve from 0 to 24 h (AUC0-24) was significantly higher than the median ISF AUC0-24 (340.4 versus 141.1 mg · h/liter; P = 0.004). There was no statistical difference in median fluconazole ISF penetration between patients receiving and not receiving vasopressors (median, 0.28 versus 0.78; P = 0.106). Both minimum and the maximum concentrations of drug in serum (Cmax and Cmin) showed a significant correlation with the fluconazole plasma exposure (Cmax, R(2) = 0.86, P < 0.0001; Cmin, R(2) = 0.75, P < 0.001). Our data suggest that fluconazole was distributed variably, but incompletely, from plasma into subcutaneous interstitial fluid in this cohort of critically ill patients with sepsis. Given the variability of fluconazole interstitial fluid exposures and lack of clinically identifiable factors by which to recognize patients with reduced distribution/exposure, we suggest higher than standard doses to ensure that drug exposure is adequate at the site of infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26596947      PMCID: PMC4750683          DOI: 10.1128/AAC.02461-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.

Authors:  Alexandra Douglas; Andrew A Udy; Steven C Wallis; Paul Jarrett; Janine Stuart; Melissa Lassig-Smith; Renae Deans; Michael S Roberts; Kersi Taraporewalla; Jason Jenkins; Gregory Medley; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

2.  Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.

Authors:  Jason A Roberts; Andrew A Udy; Paul Jarrett; Steven C Wallis; William W Hope; Raman Sharma; Carl M J Kirkpatrick; Peter S Kruger; Michael S Roberts; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2015-01-20       Impact factor: 5.790

3.  Treatment-related risk factors for hospital mortality in Candida bloodstream infections.

Authors:  Andrew J Labelle; Scott T Micek; Nareg Roubinian; Marin H Kollef
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

4.  Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.

Authors:  R Phillip Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven A Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Crit Care Med       Date:  2013-02       Impact factor: 7.598

Review 5.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

Authors:  Benoît P Guery; Maiken C Arendrup; Georg Auzinger; Elie Azoulay; Márcio Borges Sá; Elizabeth M Johnson; Eckhard Müller; Christian Putensen; Coleman Rotstein; Gabriele Sganga; Mario Venditti; Rafael Zaragoza Crespo; Bart Jan Kullberg
Journal:  Intensive Care Med       Date:  2008-10-30       Impact factor: 17.440

6.  Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?

Authors:  Gloria Wong; Scott Briscoe; Syamhanin Adnan; Brett McWhinney; Jacobus Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

7.  Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats.

Authors:  Francine Johansson Azeredo; Bibiana Verlindo de Araújo; Sandra Elisa Haas; Bruna Torres; Maiara Pigatto; Cristiane de Andrade; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

8.  Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities.

Authors:  Hilmar Wisplinghoff; Jenny Ebbers; Lea Geurtz; Danuta Stefanik; Yvette Major; Michael B Edmond; Richard P Wenzel; Harald Seifert
Journal:  Int J Antimicrob Agents       Date:  2013-10-12       Impact factor: 5.283

Review 9.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

10.  Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.

Authors:  Mahipal G Sinnollareddy; Jason A Roberts; Jeffrey Lipman; Murat Akova; Matteo Bassetti; Jan J De Waele; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; George Dimopoulos
Journal:  Crit Care       Date:  2015-02-04       Impact factor: 9.097

View more
  6 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 2.  Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization.

Authors:  Amelia N Deitchman; M Tobias Heinrichs; Vipada Khaowroongrueng; Satyawan B Jadhav; Hartmut Derendorf
Journal:  AAPS J       Date:  2016-12-09       Impact factor: 4.009

3.  ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.

Authors:  Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2019-03-25       Impact factor: 17.440

Review 4.  Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy.

Authors:  Thierry Calandra; Jason A Roberts; Massimo Antonelli; Matteo Bassetti; Jean-Louis Vincent
Journal:  Crit Care       Date:  2016-05-27       Impact factor: 9.097

5.  Choosing the Right Antifungal Agent in ICU Patients.

Authors:  Jeanne Chatelon; Andrea Cortegiani; Emmanuelle Hammad; Nadim Cassir; Marc Leone
Journal:  Adv Ther       Date:  2019-10-15       Impact factor: 3.845

Review 6.  Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches.

Authors:  Wisse van Os; Markus Zeitlinger
Journal:  Antibiotics (Basel)       Date:  2021-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.